• By Kevin E. Noonan

    The advent of a new administration always carries with it changes in how the laws are executed and applied, and patent law is both no exception and tends (at least in recent years) to appear to be fraught with dramatic changes in emphasis (at least on certain aspects of the law). This can be appreciated by a consideration of Director Dudas and the (infamous) “claims and continuation” rules fracas in the mid-aughts; a return to the Office’s more convention role of modulating application of legal precedent under Director Kappos; the more stringent application of the Mayo/Alice principles to subject matter eligibility under Director Lee; changes in such applications under Director Iancu; and DEI efforts and cooperation with FDA over drug patents under Director Vidal.

    Under the second Trump administration, the sea change in inter partes review (IPR) before the Patent Trial and Appeal Board (involving Director discretionary denials of such challenges) began this spring under Interim Director Stewart, and with confirmation of Director John Squires these changes have increased in significance and extent.

    On Friday, October 17, the Office released a Memorandum to all PTAB judges and an Open Letter to “Colleagues, Inventors, and Americans” announcing that from October 20, the Director will determine whether to institute IPR proceedings  and post-grant review (PGR) proceedings under the statutory authority provide by 35 U.S.C. §§ 314 and 324, respectively.*  According to the Letter, Congress has vested the Director with sole statutory authority to render such decisions, despite provisions under 35 U.S.C. § 3(b)(3)(B) for the Director to be able to delegate such authority, which has been the practice since IPRs and PGRs were instituted under the Leahy-Smith America Invents Act in 2012.  Such delegation typically has been to three-judge panels of PTAB judges (although expanded panels, including the Director and other PTO officials have made such decisions from time to time, there having been 21 instances to date).

    The Letter announces that “initial operational choices” had been the reason for delegation by earlier Directors, but that “experience has raised structural, perceptual, and procedural concerns inconsistent with the AIA’s design, clear language, and intent” and as a consequence the public’s “rightful expectation of impartiality” had been affected (negatively, presumably)(emphasis in Letter). These concerns included a seeming preference for IPRs over PGRs and a “very high” rate of invalidation. The Letter includes as additional concerns that there was a “perception of self-incentivization” (i.e., creating an appearance that institution decisions were made for the Board to “fill[] its own docket” (although the Letter is quick to emphasize that this perception “may be unfounded”). Further, so-called “bifurcated processes” (i.e., a preliminary review prior to Board referral), which the Letter asserts were both smart and necessary at the beginning of the AIA’s post-grant review regime were not intended to be permanent and “appears to have inadvertently produced extraordinarily high institution rates” (~95%). The Letter also makes the point that Congress had charged the Director to make institution determinations by statute and this mandate should not be easily circumvented.

    The benefits of these changes enumerated in the Letter are said to include “eliminat[ing] the appearance of self-interest,” “remov[ing] perceived referral-signal bias,” “enhanc[ing] transparency and public trust,” and “re-align[ing] the duties and responsibilities of the Director as a “Presidentially appointed and Senate-confirmed officer.”

    The Letter concludes with the following exhortation:

    In closing, the mission of America’s Innovation Agency is to lead the world in intellectual property protection. We can do so and serve the public interest only by maintaining a patent system that is fair, predictable, and respected. Returning institution authority to the Director bolsters our mission because it restores the statutory framework mandated by Congress in the America Invents Act.

    The contents, proposals, and changes in the other announcements will be the subject of following posts.

    * 35 U.S.C. § 314 reads in pertinent part:

    The Director may not authorize an inter partes review to be instituted unless the Director determines that the information presented in the petition . . . shows that there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.

    35 U.S.C. § 324:

    The Director may not authorize a post-grant review to be instituted unless the Director determines that the information presented in the petition . . . shows that there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.

  • To paraphrase Chicago Bulls legend, Michael Jordan, Patent Docs would like to announce that we are back! A few of our readers have noticed that it has been awhile since we last posted, and you may have noticed that there were a few “issues” with the way Patent Docs appeared on your browser earlier this month (see screenshot below) – as well as a few differences with the way the weblog currently appears on your browser.

    These issues and differences are due to a change in the software that we use to maintain the weblog. Since Patent Docs began publishing on October 22, 2006 – and up until today – we had been using the TypePad blogging platform. Unfortunately, TypePad announced last month that it was shutting down, effective September 30, 2025, and that bloggers would have to export their content or permanently lose that content. We have therefore moved Patent Docs to the WordPress blogging platform, and note that it may take some time before we have adjusted the settings so the weblog looks somewhat like it looked on TypePad. So we ask that you please pardon our “dust” while we get used to the new digs.

    Screenshot
  •     By Michael Borella

    USPTO SealOn August 27, 2025, the U.S. Patent and Trademark Office quietly announced that it would be deprecating its current Patent Assignment Search and Assignments on the Web assignment search portals and replacing them with a new portal accessible from Assignment Center.  The announcement states:

    Starting on September 27, 2025, Assignment Search will be live, and the two legacy systems will cease to be available.  This new, web-based application provides customers seeking patent and trademark assignment information with reliable, detailed results via a modernized interface.  Customers can perform basic searches and refine their searches using the filtering options available in the "advanced search" field of the tool.

    Just over a year ago, the USPTO informed the public that it had suffered a data breach in its assignment interface that appears when accessing a patent or application in Patent Center.  In response, the USPTO disabled this option in Patent Center, thus requiring more effort for applicants to check or confirm the status of their assignments.  But the overall inconsistency and unreliability of the current systems have been problematic.

    Particularly, the situation can be summed up as follows.  Some assignments can be viewed from Patent Center (despite what the USPTO alleges), but most patents and applications have the assignment tab grayed out.  Many can be found using Patent Assignment Search.  Sometimes Patent Assignment Search will not provide any results, even for an assignment that has been properly recorded.  In those cases, Assignments on the Web might or might not provide a result.  Both Patent Assignment Search and Assignments on the Web are periodically unresponsive, either never completing or returning no results at all.  Also, neither will show the assignment statuses of unpublished applications, even to the attorney of record.

    This means that when an applicant cannot locate an official record of an assignment by any of these means at the USPTO, they need to check whether they received a notice of recordation.  If they did, the assignment is almost certainly recorded even if Patent Assignment Search and Assignments on the Web indicate otherwise.

    Like many aspects of dealing with USPTO web-based systems that do not work as advertised, these inconsistencies cause excess delays and cost applicants money.  In particular, trying to ascertain the status of a large patent portfolio can be very time consuming, whereas previously (when things were working properly via Patent Center) it was relatively straightforward.  This is particularly problematic when an assignee is trying to use their IP assets as collateral for financing or needs to demonstrate ownership as part of a sale.  If they do not have notices of recordation on hand, the assignment status of these assets may remain unclear.

    While the USPTO's announcement of a replacement for these limited and undependable portals should be welcome, there is reason to be cautious due to the agency's recent track record.

    Notably, the USPTO's rollout of Patent Center has been and continues to be plagued with persistent technical issues that have frustrated practitioners and increased the costs of routine filings.  When Patent Center fully replaced legacy systems such as EFS-Web and PAIR last year, practitioners were subjected to bugs that disrupted even basic functions.  These errors have been described as "totally unacceptable," and what were once were straightforward submissions now take longer, create uncertainty, and can jeopardize deadlines.  The added time and expense ultimately fall on the most vulnerable applicants, particularly startups and smaller companies with limited budgets.

    The USPTO's announcement implicitly acknowledges the obvious — its current assignment portals are unreliable.  Replacing them is welcome, but the agency's execution record in deploying new platforms is mixed at best.  Without meaningful improvements in testing, responsiveness to practitioner feedback, and long-term maintenance, the new Assignment Search risks joining the growing list of USPTO systems that never quite work as intended.  For now, the legal community should be cautious until the new system has proven itself under day-to-day use.

  • By Manav Das


    Tennis ballThe U.S. Open tennis championships are currently underway in New York, with the main draw starting on a Sunday for the first time.  In the singles competition, top players like Emma Raducanu, Novak Djokovic, and Aryna Sabalenka are headlining the early rounds.  Amidst the on-court action, intellectual property (IP) remains a key component of the tennis world, extending beyond player endorsements and brand protection to include patent litigation over technologies used in the game itself.

    Indeed, tennis is not only played or decided on tennis courts.  From racquet technologies to retractable roofs, IP disputes have shaped the sport's technology, marketing, and even its venues.  We look at a few intriguing cases and storylines where decisions were not made by a chair umpire, a line umpire, or a referee, but by a judge in a courtroom or by parties to the dispute.

    A.  Patent and Technology Disputes

    Group One Ltd. v. GTE GmbH[1]

    Group One, a competitor, accused GTE GmbH and its founder, Ralf Weigel, of directly, contributorily, and willfully infringing Group One's patents related to let-detection technology.  The core of the infringement claims involved GTE's "Trinity" system used at the 2019 and 2020 U.S. Opens.  The "let-detection" systems are related to determining if a tennis ball has hit the top of the net during a serve.

    A notable issue was the court's jurisdiction over the foreign defendants (GTE GmbH and Weigel, both in Germany).  The court addressed whether service of process by email was sufficient under the Hague Convention, ultimately concluding that it was, as long as it comported with due process.  This finding is particularly relevant for practitioners dealing with international litigation.

    Another issue was Group One's attempt to hold a non-party, the United States Tennis Association (USTA), in contempt for using an allegedly infringing product.  The court denied this motion, ruling that it lacked the authority to enjoin a non-party unless it was acting in concert with a party.  The court also clarified that a non-party could not be enjoined for using a product not supplied by the defendants in the lawsuit.

    The District Court issued a default judgment against GTE and Weigel for patent infringement, false advertising, and other claims.  Group One was awarded lost profits for the 2019 and 2020 U.S. Opens, but not for other tournaments.  On appeal[2], the Federal Circuit affirmed the District Court's decisions on damages and contempt.  However, the Federal Circuit reversed the District Court's failure to award post-judgment interest and sent the case back to determine the amount.

    Prince v. Wilson (and Frolow)

    These cases[3], which reached the Federal Circuit, involved patent disputes that grew out of a licensing agreement between the two sporting goods giants.  The core issue was whether certain Wilson tennis rackets infringed claims in patents owned by Jack Frolow, to which Wilson had a license Prince, a competitor, was also involved as a licensee.

    The most significant legal takeaway from the appellate court's decision[4] was its analysis of "marking estoppel."  Frolow argued that because Wilson had marked some of its racquets with the patent number, it should be "estopped" from later claiming those same racquets did not infringe the claims in that patent.

    The Federal Circuit rejected the doctrine of marking estoppel, stating it was not a recognized legal principle.  However, the Court did find that the act of marking a product with a patent number serves as circumstantial evidence, an "extrajudicial admission", that the product falls within the patent's scope.  The Federal Circuit reversed the District Court's summary judgment, ruling that the evidence of Wilson's marking was sufficient to create a genuine issue of material fact for a jury to decide.  In essence, while marking does not automatically create liability, it can be powerful evidence of infringement.

    Retractable roofs and trade secrets at Arthur Ashe Stadium

    The engineering firm Uni-Systems LLC, a developer of retractable roof technology, filed a lawsuit[5] in 2017 against several contractors and suppliers behind the U.S. Open's Arthur Ashe Stadium roof project.  The suit, filed in the U.S. District Court for the Eastern District of New York, alleged both patent infringement and trade-secret misappropriation.

    The trade secret dispute centered on an earlier collaboration between Uni-Systems and one of the defendants, Hunt Construction Group, Inc., for a retractable roof project at the University of Phoenix Stadium (now State Farm Stadium) in Arizona.  Uni-Systems alleged that Hunt, in collaboration with the engineering firm Hardesty & Hanover, used a maintenance contract on the Arizona project as a way to steal Uni-Systems' proprietary technology and trade secrets, including operational software and detailed design specifications.

    The lawsuit also accused the defendants of infringing two of Uni-Systems' patents related to retractable roof design:  U.S. Patent No. 6,789,360[6] ("Retractable Roof System for Stadium") and U.S. Patent No. 7,594,360[7] ("Lateral Release Mechanism for Movable Roof Panels").  Uni-Systems claimed that the roofs at both Arthur Ashe Stadium and the new Louis Armstrong Stadium infringed the claims of these patents.

    The case involved numerous defendants, including the USTA, Skanska USA (as a successor to Hunt Construction), and other engineering and construction firms.  While the specific terms of a final resolution are not public, court filings and legal news reports indicate the case was ultimately settled.  Venue construction disputes highlight how stadium infrastructure is laden with IP risk.

    B.  Trademarks, False Advertising, and Brand Control

    Penn (Head) v. Dunlop

    In a case of false advertising under the Lanham Act, Head USA Inc. and its subsidiary, Penn Racquet Sports Inc., sued rival Dunlop International Ltd. over its claim of selling the "#1 ball in America."  The lawsuit was filed in federal court in Connecticut[8].  Penn accused Dunlop of misleading the public by advertising its tennis balls with the slogan "The World's No. 1 Ball" and a related claim of having a 70% global market share.  Penn argued that Dunlop's claims were factually false and that Penn, in fact, held the largest market share in the United States, making Dunlop's "No. 1" claim misleading to American consumers.

    The case is an example of a Section 43(a) Lanham Act claim.  This federal law governs false advertising and unfair competition.  For a claim to succeed, the plaintiff must typically show that the defendant made a false statement of fact in advertising that is material and likely to deceive a substantial portion of the target audience, causing injury to the plaintiff.  The burden of proof would have fallen on Dunlop to substantiate its "#1" claim, likely through reliable market data or surveys.

    While the specific terms of the resolution are not publicly available, such high-profile false advertising cases are often resolved through confidential settlements.

    Babolat false-advertising class action

    This lawsuit[9] alleged that Babolat misled consumers into believing that the tennis rackets sold at retail were identical to those used by professional players, such as Rafael Nadal.  This practice, known as "misleading endorsements" or "product parity claims," formed the basis of the legal action.  The consumers argued that they were induced to purchase the commercial racquets under the false premise that they were getting the same high-performance product used by elite athletes, when in fact, the pro-player frames were often custom-made with different materials, specifications, and weight balances.

    Federal Trade Commission (FTC) guidelines[10] for endorsements require that endorsements reflect the honest opinions, findings, or experiences of the endorser.  When a product is not truly the same, a company risks violating these rules and triggering liability.

    The case sheds light on the frequent practice in professional sports of using "pro stock" or custom equipment that is not available at retail.  This creates a legal gray area where the line between aspirational advertising and deceptive marketing can become blurred.  Companies must be careful to avoid implying a direct link between the pro gear and the retail product if they are not, in fact, identical.

    The case resulted in a class action settlement for $4.5M, underscoring how endorsements and product parity claims can trigger liability.  The significant settlement amount serves as a warning to brands that the financial and reputational costs of misleading advertising can be substantial, especially when consumer trust is a key part of the brand's value proposition.

    Roger Federer's 'RF' logo

    This dispute centered on the ownership of the "RF" logo, a stylized monogram of Roger Federer's initials that became synonymous with his brand.  When Roger Federer was in a long-term sponsorship deal with Nike, the company created the "RF" logo for him.  As part of their contract, Nike registered the "RF" trademark in various classes covering clothing and footwear, making it the legal owner of the intellectual property.  When Federer left Nike for Uniqlo, Nike still owned the 'RF' trademarks.

    This meant that even though they were Federer's initials, he could not use the mark with his new sponsor without a license from Nike.  Federer said[11] his hope that Nike would be "nice and helpful in the process" of returning the logo, emphasizing that they were his initials and "not theirs forever."

    The dispute was not a formal lawsuit in court but a negotiation that took place behind the scenes.  Nike stopped selling "RF"-branded merchandise, and after a period of approximately two years, they assigned the trademark rights to Tenro AG, a company owned by Federer that manages his intellectual property[12].  The details of the agreement were not made public, but it is widely believed that Federer paid a considerable sum to regain control of his brand.  Tenro owns[13] other trademarks associated with Federer.

    The dispute serves as a cautionary tale, illustrating that even an individual's own initials can become the property of a corporation if the company is responsible for creating and registering the trademark.  The outcome shows the immense leverage a top-tier athlete holds.

    This case highlights the crucial importance for athletes to address intellectual property ownership in their sponsorship contracts.  A better-structured deal from the outset could have included a clause that automatically transferred trademark rights back to the athlete upon the termination of the agreement.

    C.  Copyrights

    Artist v. USTA

    In Noonan v. USTA[14], the dispute arose over a T-shirt sold by the USTA at the US Open that featured a design inspired by the New York City subway map.  Mark Noonan, a freelance artist and designer, had created a distinctive, stylized version of the New York City subway map as part of his "NYC Subway Series" artwork.  Noonan claimed that the USTA sold t-shirts at its gift shops during the 2011 U.S. Open that copied his unique "subway-style map" design, which featured tennis-related locations and was registered with the U.S. Copyright Office.  He alleged that the USTA's shirt was a "blatant copy" of his work, infringing on his copyright.

    While a factual map itself is not copyrightable, the artistic expression and selection of elements, colors, and design can be.  Noonan's case rested on the argument that his specific stylized design was original enough to warrant copyright protection.

    The case was also ultimately settled out of court.  The specific terms of the settlement were not publicly disclosed.  The case serves as a good example of the risks that large organizations face when using artistic designs for merchandise without properly licensing the work from its creator.

    D.  Key Takeaways

    Game-day success relies just as much on foresight in IP strategy as it does on on-court performance of the players.  Each case provides significant takeaways both for sports executives and legal practitioners:

    Group One v. GTE GmbH: Courts can find that email is a valid method for international legal service, and a plaintiff cannot seek to hold a non-party in contempt for using an allegedly infringing product not supplied by the defendants.

    Prince v. Wilson (and Frolow): While not legally binding, marking a product with a patent number can serve as powerful circumstantial evidence of infringement in court.

    Uni-Systems v. US Open Contractors: A company's trade secrets can be protected even during a collaborative project, and IP risks extend to complex infrastructure like retractable stadium roofs.

    Penn (Head) v. Dunlop: Superlative advertising claims like "#1" must be factually substantiated with data to avoid liability under false advertising laws.

    Babolat Class Action: Brands face significant liability for misleading consumers with product parity claims, especially when pro-stock equipment is different from what is sold at retail.

    Roger Federer's 'RF' Logo Saga: Athletes should secure ownership of their IP in endorsement contracts, as a corporation that creates a logo can legally own it, even if it is based on an athlete's name.

    Artist v. USTA: Large organizations must properly license creative designs for merchandise, as even stylized artistic interpretations of public domain items, like maps, are protected by copyright.

    [1] Group One Ltd. v. GTE GmbH, 523 F. Supp. 3d 323 (E.D.N.Y. 2021)

    [2] Group One Ltd. v. GTE GmbH, No. 24-1273 (Fed. Cir. Aug. 21, 2025)

    [3] Prince Sports Group, Inc. v. Wilson Sporting Goods Co., 42 F.3d 1408 (Fed. Cir. 1994) (addressing jurisdictional issues and the scope of appealability regarding a settlement and subsequent patent dispute), Prince Sports Group, Inc. v. Wilson Sporting Goods Co., 91 F.3d 167 (Fed. Cir. 1996) (addressing summary judgment on noninfringement and the district court's refusal to rule on patent invalidity), Frolow v. Wilson Sporting Goods Co., 710 F.3d 1303 (Fed. Cir. 2013) (addressed breach of a license agreement and whether certain tennis racket models qualified as "Licensed Articles" under a patent license.)

    [4] Frolow v. Wilson Sporting Goods Co., 710 F.3d 1303 (Fed. Cir. 2013)

    [5] Uni-Systems, LLC v. U.S. Tennis Ass'n, Inc., 350 F. Supp. 3d 143 (E.D.N.Y. 2018)

    [6] https://patents.google.com/patent/US6789360B2

    [7] https://patents.google.com/patent/US7594360B2

    [8] Head USA Inc. et al. v. Dunlop Sports Group Americas Inc. et al., Case No. 3:12-cv-00624-AWT (D. Conn. filed Apr. 30, 2012)

    [9] Ahdoot et al. v. Babolat VS North America Inc. et al., Case No. 2:13-cv-02823 (C.D. Cal. filed Apr. 17, 2013)

    [10] Section 5 of the FTC Act (15 U.S.C. § 45)

    [11] https://www.tennisworldusa.org/tennis/news/Roger_Federer/85009/roger-federer-recovers-rf-logo-from-nike/ (last accessed August 22, 2025)

    [12] https://www.sportspro.com/news/roger-federer-rf-logo-us-trademark-tenro-nike-uniqlo/#:~:text=Roger%20Federer%20has%20reclaimed%20his,and%20Trademark%20Office%20(USPTO). (last accessed August 22, 2025)

    [13] https://www.trademarkia.com/owners/tenro-ag (last accessed Aug. 23, 2025)

    [14] Noonan v. U.S. Tennis Ass'n, Case No. 1:11-cv-06103 (S.D.N.Y. filed Aug. 31, 2011)

  • By Michael Borella and Walter DeGroft[1] –

    USPTO SealEach year since 2021, we have examined how the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) has been deciding appeals of § 101 rejections from examiners.[2]  And so far, the numbers have been remarkably similar.  2024 was no exception — applicants continued to face affirmance rates that were not only very high, but stubbornly consistent with prior years.  The story here is not one of progress or meaningful change, but of inertia where an entrenched status quo provides predictability by denying patents for a wide range of inventions.

    The overall affirmance rate for 2024 was 88.6%.  As shown below, this is in line with affirmance rates from previous years.

    Table 1
    Put another way, about 7 out of 8 appeals from examiner rejections on grounds of § 101 in 2024 were affirmed by the PTAB.  Conversely, the likelihood of a successful PTAB 101 appeal is 11.4%.  This is approximately the same chance of flipping a coin 3 times and getting no heads (12.5%), the rate of left-handedness in the U.S. (~10%), or your cat coming when you call it (scientifically unverifiable but feels about right).

    The persistently high affirmance rate of § 101 rejections at the PTAB is best understood as a direct consequence of the Supreme Court's decision in Alice Corp. v. CLS Bank.  The two-step framework articulated in Alice provides little concrete guidance for practitioners, examiners, or judges.  The Court deliberately avoided defining what constitutes an "abstract idea" or when an "inventive concept" suffices to transform such an idea into patent-eligible subject matter.  This vagueness has left lower tribunals and the USPTO with a test that is inherently malleable.

    The Federal Circuit's subsequent case law has not resolved the ambiguity.  Instead, it has produced a patchwork of inconsistent precedents, where eligibility may hinge on subtle distinctions that are difficult to reconcile.  Cases such as Enfish v. Microsoft and McRO v. Bandai suggest that claims directed to specific technological improvements can survive § 101 scrutiny, while decisions like Electric Power Group v. Alstom or ChargePoint v. SemaConnect represent how readily claims can be characterized as unpatentably "abstract."  The result is a body of law where outcomes depend heavily on framing and analogy, not clear statutory or judicial criteria.

    While individual examiners at the USPTO apply § 101 in a notoriously inconsistent and personalized fashion, the PTAB consistently errs on the side of ineligibility.  The PTAB's affirmance rate is thus less a reflection of the merits of applicants' arguments and more a predictable byproduct of an eligibility test that lacks objective criteria and is skewed against applicants.  The USPTO's recent subject matter eligibility memo merely reiterates the vagueness of the test, failing to provide anything close to a clear distinction between eligible and ineligible inventions.[3]

    In any event, our data gathering process was as follows.  From the PTAB's search interface, we specified the following criteria:  decision dates between January 1, 2024 and December 31, 2024, a proceeding type of "appeal", a decision type of "decision", and an issue type of "101".  These search results were overinclusive and thus required filtering and a degree of manual review.

    We only included decisions in which the applicant appealed an examiner's Alice-based § 101 rejection and the PTAB ruled on this basis of appeal.  To simplify the analysis, we considered a decision to be an "affirmance" of the examiner's § 101 rejection if the PTAB held at least one claim invalid under § 101.  Excluded cases where those in which: (i) the appeal was not of a § 101 issue but the PTAB set forth a new grounds of rejection based on § 101, and (ii) the appeal was of a § 101 issue but the PTAB did not decide the case on § 101 grounds (e.g., the examiner withdrew the § 101 rejections after the appeal was filed).  This gave us 692 qualifying appeals, of which 613 resulted in affirmance on § 101 grounds.

    In addition to the abysmal overall affirmance rate of 88.6%, we broke the data down by USPTO technical center (TC).  For sake of comparison, we also included corresponding data from 2023 and 2022 in the table below (click on table to enlarge).  To provide a sense of scale, entries in italics are for technical centers with 40 or more 101 appeals for that year.

    Table 2
    As expected, TC3600, where most business method inventions submitted to the USPTO land, continues to have the majority of appeals (488 of 692) as well as the worst affirmance rate.  This shows that appeals from this TC are for applications that the PTAB treats as virtually per se ineligible.  TC3700, which also handles some business methods, is nearly as bad, reinforcing the point that the PTAB views any claim drawn to so-called "non-technical" features as almost certainly doomed.  But high affirmance rates are evident across nearly all art units in which software-implemented inventions are examined, and even life sciences inventions are far from safe.  The persistence of these numbers year after year confirms that the PTAB's application of § 101 is not a matter of discretion or shifting doctrine, but a structural feature of an unworkable test.

    Another set of factors we considered were the grounds under which claims were found to be abstract by the PTAB.[4]  In line with USPTO practice, a claim is "abstract" when it recites mathematics, mental steps, or methods of organizing human activity.  Of the affirmances, 18.3%, 63.9%, and 73.41% were based on these categories, respectively.  Compared to 2023's numbers of 17.3%, 46.7%, and 68.1%, we see mathematics holding steady, while there was a sharp uptick in affirmances based on the mental steps category.

    We have noticed, at least anecdotally, that the mental steps category is appearing with greater frequency in rejections of AI-based inventions.  One explanation could be that the PTAB is simply reviewing more appeals in this technology area.  The methods of organizing human activity category, which is already high, ticked up further.  AI-based inventions directed to automation of tasks previously performed by a human may be a cause of this.

    Finally, we considered situations where the applicant appeals on grounds other than § 101 (e.g., §§ 102 or 103) but the PTAB decision included a sua sponte § 101 rejection.  This occurred 9% of this time in 2024, which is consistent with the 10% of 2023.  For applicants, the practical consequence is clear.  Even if you overcome the hurdles of §§ 102 and 103 at the PTAB, there is a non-negligible chance that § 101 will be raised against you for the first time.  Such a rejection increases the cost, delay, and uncertainty for the application, and reinforces the systemic disadvantage patentees face under the current eligibility regime.

    In short, applicants faced the same uphill battle in 2024 that they did in the previous years, and nothing in these statistics suggests that the trend will change absent intervention from Congress or the Supreme Court.  As Judge Paul Michel has warned, this kind of unpredictability makes patents unreliable assets of questionable value.  The consequences fall heaviest on startups and small businesses, which depend on enforceable patents to raise capital and challenge incumbents.  The current affirmance rates all but guarantee the opposite, fortifying the position of dominant players while draining the lifeblood from emerging companies.

    [1] Walter DeGroft was a 2025 Summer Associate at MBHB.  He is currently a law student at the Chicago-Kent College of Law.

    [2] Patent Docs has published our previous articles for 2021, 2022, and 2023.

    [3] https://www.uspto.gov/sites/default/files/documents/memo-101-20250804.pdf

    [4] The vast majority of the § 101 appeals were of software, business methods, and engineering-related technologies.  Life sciences § 101 appeals were mostly based on the "law of nature" exclusion to patentability rather than the "abstract idea" exclusion.  Very few (less than 10) life sciences appeals were in this data set.

  • An inevitable and tragic outcome

    By Kevin E. Noonan

    Judge Newman_1Congress in writing laws is faced with a dilemma.  On the one hand the laws must be sufficiently clear and specific to enable enforcement, but on the other, the myriad of circumstances that can arise make it impossible to delineate with sufficient prescience the multitude of situations that can fall within the scope of the statute.  Courts are the usual arbiters of how the law should be interpreted and applied, under Marbury v.  Madison and 230 years of subsequent precedent.  The question of what happens when it is the court itself whose practices and procedures are at issue has arisen in Judge Pauline Newman's challenge to her suspension under the Judicial Councils Reform and Judicial Conduct and Disability Act of 1980.  As set forth in the D.C. Circuit Court of Appeals opinion against that challenge, the Court decided that its hands were tied by the statute itself (as interpreted by the Court under McBryde v. Committee to Review Circuit Council Conduct & Disability Orders of the Judicial Conference of the United States, 264 F.3d 52 (D.C. Cir. 2001)), which held that "Congress precluded our jurisdiction over statutory and as-applied constitutional challenges to judicial council orders."  This was the decision even though in their opinion the Court states that "our reasons for affirming are unrelated to the strength of Judge Newman's statutory claim or as-applied constitutional claims.  Nor does our decision reflect our views of the underlying dispute or of Judge Newman's suspension."

    The decision was ultimately jurisdictional, the panel deciding that their jurisdiction only extended to "Judge Newman's facial constitutional challenge to the Act's case suspension provision," which failed on the grounds that the challenged provision has applications that are constitutional (a rather "all or none" approach no matter how proper).  The statutory provision purportedly tying the Court's hands, § 357(c) entitled "No Judicial Review" states that "all orders and determinations, including denials of petitions for review, shall be final and conclusive and shall not be judicially reviewable on appeal or otherwise."  Which seems not only plain on its face but to express Congress's clear intentions, upon which the D.C. Circuit panel relied in affirming the District Court's dismissal of Judge Newman's as-applied constitutional claims and statutory claim for lack of jurisdiction.

    Application of the law, and specifically § 357(c), is governed by Supreme Court precedent, particularly Webster v. Doe, 486 U.S. 592, 603 (1988), where a statutory bar to judicial review should be upheld to preclude review of constitutional claims "only if there is clear and convincing evidence'" of Congressional intent, the opinion citing Ralls Corp. v. Comm. on Foreign Inv. in U.S., 758 F.3d 296, 308 (D.C. Cir. 2014).  The panel turned to McBryde in holding that this Circuit Court of Appeals had performed this judicial analysis and found sufficiently "clear and convincing" evidence to uphold the bar to Judge Newman's constitutional challenge.  In particular, the Court in McBryde held that there was insufficient evidence of Congressional intent regarding facial challenges to the statute's constitutionality, but there was sufficient evidence to do so regarding "as applied" challenges. It was in this latter category to which the Court understood Judge Newman's challenges reside.  And the judges on the panel recognized that they are bound by the earlier decisions of the Court unless overturned by "intervening Supreme Court precedent."

    The opinion then turns to Judge Newman's arguments that the Supreme Court has effectively overruled McBryde, specifically (and fittingly) in SAS Institute, Inc. v. Iancu, 584 U.S. 357 (2018), asserting that the Supreme Court's decision "suggests that even an explicit statutory bar cannot preclude judicial review of claims that an agency exceeded its statutory authority."  (It is necessary to consider in this argument the mention in an earlier footnote that "our court has treated judicial councils and the Judicial Conference as administrative rather than judicial bodies," which makes this citation germane.)  The panel was unpersuaded by this argument, because they discerned as a distinction that in SAS the statutorily preclusion was with regard to "whether to institute an inter partes review" (emphasis in opinion) whereas the challenge was directed to "how the Director conducted his inter partes review" and thus outside the scope of the challenged statutory provision (35 U.S.C. § 314(d)).

    The panel also rejected Judge Newman's argument that the addition of a severability clause to the statute in 2002 "expressly contemplates 'as applied' challenges to the Act being adjudicated in Article III courts," if only because its scope was generic and did not state that an Article III court could consider as-applied challenges.  Nor did the panel agree that the failure of the Judicial Conference to consider constitutional issues undermined the reasoning in McBryde's that the Judicial Conferences themselves could or would consider these issues (the panel recognizing that the Judicial Conference here pointedly declined to consider Judge Newman's constitutional challenges).

    Finally, the Court refused Judge Newman's recourse to Axon Enterprise, Inc. v. FTC, 598 U.S. 175 (2023), and Free Enterprise Fund v. Public Company Accounting Oversight Board, 561 U.S. 477 (2010), to the extent that Judge Newman argued those cases "held that all constitutional questions 'are outside the scope of agencies' expertise' and so must be reviewable in federal courts."  But "neither case involved an explicit jurisdiction-stripping provision like Section 357(c)" (emphasis in opinion); in those cases the preclusion was implied according to the Court, and in such cases the standard is not a clear and convincing evidence of Congressional intent.

    The opinion then addresses the deficiencies of Judge Newman's reasoning to as-applied challenges.  These included a footnote in McBryde that the Judge contended evinced an opinion that a court would have jurisdiction over as-applied challenges should they arise.  This opinion terms this reading of McBryde to be "implausible" in view of the remainder of the McBryde opinion. Similarly the panel dismissed Judge Newman's argument that McBryde (nor the statute) did not preclude her due process claims or the Judicial Conference's refusal to transfer her case to a different circuit, because "Judge Newman may be right that the Act provides no means to petition the Conference for interlocutory review of the Council's transfer decision.  But the Act does provide for Conference review of any final council action stemming from a case that was not transferred," which Judge Newman unsuccessfully attempted to employ.

    Having explained the portions of Judge Newman's arguments over which the Court did not have jurisdiction the opinion turned to those that it does, the Judge's facial challenge to the statute's case-suspension provisions.  The panel acknowledges the difficulty in prevailing in such challenges.  The most determinative of these difficulties is Judge Newman's acknowledgment that there are applications of the statute that pass constitutional muster, where a facial challenge demands that there be no such circumstances or applications.  In this portion of the opinion, the Court sets forth those concessions and their effect on the Judge's arguments, including that "short suspensions from receiving new case assignments" are constitutional under certain circumstances.  But Judge Newman has not been able to show "no set of circumstances . . . under which the law would be valid" or that it "lacks a plainly legitimate sweep," citing Comm. on Ways & Means v. Dep't of Treasury, 45 F.4th 324, 339 (D.C. Cir. 2022).  And ("indeed") the panel appreciates that Judge Newman did not attempt to make this showing, rather arguing that how the statute was applied to her was unconstitutional.  Somewhat unkindly, the opinion states that the Judge's argument "misunderstands the law governing facial constitutional challenges" at least in this context (begrudging that in other contexts, such as the First Amendment, "statutes may sometimes be deemed facially invalid where only a subset of their applications are unconstitutional," citing United States v. Hansen, 599 U.S. 762, 769 (2023), and stating that this is a special case due to the importance of constitutionally protected speech).  The Court also dismissed Judge Newman's invitation to adopt a "narrowing construction" of the statute because in order to properly do so the panel states that first Judge Newman would have had to raise "a serious constitutional question," which, in their view, Judge Newman has not done.

    The opinion ends with two points the panel sought to emphasize.  The first is that they did not (and assert that they could not) consider the merits of Judge Newman's as-applied constitutional claims.  In an apparent nod towards the respect Judge Newman has certainly earned, the Court states that "Judge Newman has posed important and serious questions about whether these Judicial Conduct and Disability Act proceedings comport with constitutional due process principles and whether her ongoing suspension comports with the structure of our Constitution" and that their failure (or more correctly refusal) to address those questions "is no indication that her arguments lack merit, nor signals how we might have addressed them if we were able."  Their hands are tied, according to the opinion, because "precedent strips us of authority to consider those challenges," which is the only reason the panel did not address them.

    The second point is a reiteration that the panel was unable to overrule McBryde but nevertheless the Court recognizes that there are reasons to think that case was wrongly decided.  One reason is that the "seeming absence of a judicial forum to address [Judge] Newman's as-applied constitutional claims itself raises constitutional concerns."  The opinion states that "Judge Newman presents substantial arguments that her suspension—which has now lasted nearly two years, with a third year recommended—threatens the principle of judicial independence and may violate the separation of powers" as well as the due process violations Judge Newman asserted and the Court did not reach.  But as it stands under the law, Judge Newman cannot raise her as-applied constitutional arguments before any Article III court and is left at the consideration (if not mercy) of the Federal Circuit Judicial Council and Judicial Conference.

    In a footnote, the opinion speculates that Judge Newman may have the option of asking the Supreme Court to review the Judicial Conference orders under a writ of mandamus, but the Circuit Court deigned not to express an opinion on this possibility.

    Under the circumstances, it appears that Judge Newman has three options remaining:  to succumb to the demands of the Judicial Council to submit to medical and psychological testing by doctors not of her choosing; to continue in limbo under suspension; or to step down from the bench.  No one but the Judge herself can provide any relevant counsel.  But the circumstances under which the current situation has arisen and persisted can certainly and properly be decried and the Judge herself be wished Godspeed.

  • By Kevin E. Noonan

    Federal Circuit SealThe Federal Circuit affirmed a decision by the U.S. Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) in an inter partes review prompted by an infringement allegation in DexCom, Inc. v. Stewart (nonprecedential).  The dispute created an opportunity for the Court to acknowledge the importance of the "expanded and flexible" approach to obviousness determinations occasioned by the Supreme Court's decision in KSR Int'l. Co.  v. Teleflex. Inc., 550 U.S. 398 (2007), and also the question of the extent to which prior art containing alternative embodiments, only one of which is relevant to obviousness requires evidence that the skilled artisan would have (not only could have) chosen the embodiment that supported an obviousness determination.

    The case arose in an inter partes review proceeding against DexCom's U.S. Patent No. 10,702,193* brought by Abbott Diabetes Care, Inc.** and asserting invalidity for obviousness against Claims 1–3 and 11–13.  The '193 patent was directed towards glucose monitoring in patients using an implantable "transcutaneous continuous glucose sensor system."  The opinion explains that the invention sought to overcome a local inflammatory response, termed a "foreign body response" that caused implanted devices to lose their function over time, by using a "barrier cell disruptive layer" configured with a number of electrode layers separated by layers of non-conductive material.  Claim 1 was set forth in the opinion as being representative:

    1.  A transcutaneous continuous glucose sensor system comprising:
        a substantially planar sensor, the sensor comprising:
            a first conductive layer associated with a first electrode;
            a first non-conductive layer located at least in part over the first conductive layer;
            a second conductive layer associated with a second electrode, wherein the second conductive layer is located at least in part over the first non-conductive layer;
            a second non-conductive layer located at least in part over the second conductive layer;
            a third conductive layer associated with a third electrode, wherein the third conductive layer is located at least in part over the second non-conductive layer; and
            a membrane located over at least a portion of a working electrode;
        wherein at least one of the first electrode, the second electrode, or the third electrode is the working electrode, and wherein the working electrode is configured to measure a signal indicative of a glucose concentration.

    The specification of the '193 contains inter alia this drawing of the claimed device:

    Image 1which is described thusly in the '193 patent:

    The sensor typically comprises a working electrode 21, a reference electrode 20, and an optional counter electrode 22. These electrodes may be insulated from each other by insulative layers 28 and further be housed in housing 10.  The reference electrode 20 provides a stable – voltage electrode relative to which the voltage of the working electrode 21 can be controlled or detected.  The optional counter electrode 22 draws the current flowing through the working electrode 20 so that the current through the reference electrode 20 is kept at a minimum, thus maintaining its voltage stability.  The end surfaces of all three electrodes are advantageously coated with membrane system 32, which may comprise a layer of glucose oxidase enzyme.  The membrane may then be coated with the barrier cell disruptive biointerface 33.

    DexCom brought suit against Abbott for infringement and Abbott petitioned for inter partes review. Abbott's obviousness challenge relied as the primary reference on U.S. Patent Application No. 2005/0215871, arguing that Figures 4A, 4B, and 2A were sufficient to establish obviousness:

    Image 2
    Figure 4A illustrates a three-electrode sensor, and Figure 2A shows a two-electrode sensor with the electrodes separated by a plastic (non-conductive) layer in a "stacked fashion."  Abbott argued that this disclosure would have been understood by the skilled worker to show that "the three conductive layers associated with the electrodes are located overtop each other in a stacked fashion," relying on expert testimony that "Figure 4A confirms the stacked arrangement because one of the electrode 'trace' lines connecting an exterior electrode to the insertion tip covers the other two trace lines."  Abbott also argued that inserting non-conductive layers between the electrodes would have been obvious in order to avoid short circuits between the electrodes.

    In its Final Written Decision, the PTAB held that all challenged claims were obvious.  The Board was convinced that Figure 4A disclosed three electrode layers "located overtop each other in a stacked fashion," reinforced by the disclosure in Figure 2A.  This appeal followed.

    The Federal Circuit affirmed, in an opinion by the Honorable Nina Y. Wang, District Judge, U.S. District Court for the District of Colorado, sitting by designation, joined by Chief Judge Moore and Judge Stoll.  The panel rejected DeCom's argument that the Board misread Figure 4A in the Feldman reference to infer that the electrode layers were stacked, and that other configurations could be inferred with equal likelihood.  This  this failure, according to DexCom should have precluded the Board's decision from being supported by substantial evidence.  The panel contended that, on the contrary this is a misreading of the Board's decision.  The opinion states that the standard is that the Board's interpretation was one interpretation relevant to the issue of obviousness of the challenged '193 patent claims, and that what was claimed in those claims was encompassed by the Feldman disclosure, crediting Abbott's expert's testimony.  The Court relied on Bradium Techs. LLC v. Iancu, 923 F.3d 1032, 1049 (Fed. Cir. 2019), for the principle that a reference should be interpreted "not only for what it expressly teaches, but also for what it fairly suggests" to a skilled artisan.  The Board properly considered, according to the panel, that "a skilled artisan would have interpreted Feldman as encompassing the stacked electrode arrangement" and that this was substantial evidence supporting the decision.  While consistent with the case law relied upon by the Court, this interpretation seems to risk hindsight reasoning without some indication that the Board's interpretation was how the skilled worker would have, not just could have, interpreted the reference this way.  It appears from the opinion that the panel believed Abbott's expert's testimony was sufficiently convincing to find substantial evidence support for the Board's decision.

    The Court also considered DexCom's arguments to be a further misreading of the Board's decision with regard to whether the Board held that Feldman disclosed the five-layer electrode configuration or just rendered it obvious (the panel also interpreting these arguments as being inconsistently argued by DexCom) (emphasis added).  The panel considered DexCom's argument to be that "an obvious but undisclosed arrangement necessarily requires modification" but because Abbott never argued a need for modifying Feldman DexCom lacked the opportunity to respond to this argument during the IPR.  In addition, DexCom complained that the "Board failed to make the requisite fact-findings regarding a skilled artisan's modification of Feldman," and thus applied an incorrect obviousness standard.  The Court agreed that "there is no such 'dichotomy' between disclosure and obviousness, and that the Board's decision d[id] not rely on modifying Feldman to achieve the claimed arrangement" to which the panel also agreed.

    The panel further interpreted the Board's decision as relying on the "expansive and flexible approach" that permits a court (or the Board) to "take account of the inferences and creative steps that a person of ordinary skill in the art would employ" under KSR Int'l. Co.  v. Teleflex. Inc., 550 U.S. at 415, 418.  It was enough according to the Board, that Feldman disclosed the five-layer electrode claimed by the '193 patent; having disclosed other "alternative" configurations did not negate this disclosure for an obviousness determination.

    Lastly, DexCom argued that the Board was incorrect for considering Figure 4A as prior art because the filed application, which was properly prior art and had fewer clear-cut drawings, qualified but the published application should not.  DexCom and the panel recognized that this would require the Court to adopt a new evidentiary rule in IPRs, but the panel was able to avoid ruling on this issue on the grounds that DexCom waived the argument by not raising it post-institution (despite having done so in its pre-institution response, citing Parus Holdings, Inc. v. Google LLC, 70 F.4th 1365, 1373 (Fed. Cir. 2023), for the rubric that "[b]y raising an argument in its Preliminary Response, but not its Response, a patent owner waives said argument").

    * The opinion recites the patent number as 10,792,193; the correct patent number is 10,702,193.
    ** As set forth in a footnote, Abbott Diabetes Care, Inc. withdrew from the appeal prior to oral argument, and Acting Director Coke Morgan Stewart intervened in the appeal, relying on Abbott's brief.

    DexCom, Inc. v. Stewart (Fed. Cir. 2025)
    Nonprecedential disposition
    Panel: Chief Judge Moore, Circuit Judge Stoll, and District Judge Wang
    Opinion by District Judge Wang

  • By Kevin E. Noonan

    Federal Circuit SealA patent applicant dissatisfied by an patent examiner's rejection of that applicant's claims in ex parte prosecution has recourse by appeal to the Patent Trial and Appeal Board (PTAB) under 35 U.S.C. § 134, and to the Federal Circuit thereafter under 35 U.S.C. § 141.  While there is no right without a remedy (ubi jus ibi remedium) that remedy can be fleeting, as illustrated by In re BAC IP B.V. (non-precedential) (albeit illuminative).

    Appellant's appeal was from a decision by the PTAB affirming an Examiner's Final Rejection of claims 77-83 and 85-94 in U.S. Application No. 16/282,082* that were directed to a method for purifying mammalian immunoglobulin antibodies, for failing to satisfy the written description requirement of 35 U.S.C § 112(a). Claim 77 is representative:

    A method for the purification of a molecule comprising an epitope present in the Fc domain of a human IgG antibody, the method comprising the steps of:
        (a) bringing a sample comprising the molecule comprising the epitope present in the Fc domain of a human IgG antibody into contact with an immunoadsorbent material comprising a variable heavy-heavy (VHH) antigen-binding protein under conditions that allow for binding of the molecule to the immunoadsorbent material;
        (b) optionally, performing a washing step; and
        (c) eluting the bound molecule comprising the epitope present in the Fc domain of a human IgG antibody under conditions that decrease the affinity between the molecule and the VHH antigen-binding protein,
            [(i)] wherein the VHH antigen-binding protein has binding affinity for the Fc domain of the human IgG molecule but does not have binding activity for the Fc domain of a mouse, a bovine, a rat, a Syrian hamster, a guinea pig, a dog, a cat, a goat, or a sheep IgG molecule, and
            
    [(ii)] wherein the VHH antigen binding protein comprises four framework regions, FR1 to FR4, and three complementarity determining regions, CDR1 to CDR3, that are operably linked in the order FR1-CDR1-FR2-CDR2-FR3- CDR3-FR4, wherein the CDR3 region comprises the amino acid sequence Arg Arg Phe Gly Ser Ser Glu Trp Asp Tyr (SEQ ID NO: 108).

    (wherein the italicized portion of the claims raised the written description issues that were the basis for the examiner's final rejection).  The bases for the PTAB's decision (which adopted the Examiner's reasoning) were, first, that "the claims cover a large genus of VHH antigen-binding proteins"; second, that "the specification of the '082 application discloses only one VHH antigen-binding protein meeting each requirement of claim 77"; and third, that "the specification does not disclose a structural feature shared by each member of the species of claim 77."

    The Federal Circuit affirmed, in a decision by Judge Lourie joined by Judges Prost and Stoll.  The panel rejected Appellant's argument that the Board's determination was not supported by substantial evidence.  As the Court saw it, the Examiner was correct in the three bases affirmed by the Board.  Regarding the "large genus of VHH antigen binding proteins," the opinion asserts that this conclusion was based on correct claim construction which was consistent with the language of claim 77 and the specification.  The specificity of the amino acid sequences recited in claim element (c)(ii) for CDR3 of the VHH protein did not overcome the lack of such specificity for CDRs 1 or 2.  The disclosure of 49 different species of amino acid sequences for CDRs 1 and 2 in the specification also did not suffice for the panel, because the scope of claim 77 was not limited to those sequences.  The Court opined that "the claims and specification place effectively no constraints on the amino acid sequences that can constitute the CDR1 and CDR2 regions, and therefore the claimed VHH antigen-binding proteins," which supported the Examiner's conclusion that the claimed genus is broad, and was supported by substantial evidence.  The panel rejected BAC's argument that the genus was narrow because the specification only disclosed 15 VHH antigen-binding proteins defined by function and only one having the sequence recited in claim element (c)(ii).  According to the Court, the proper determination of written description satisfaction is not limited to what is disclosed in the specification but rather depends upon the scope of the claim as properly construed, which in this instance encompassed a broad genus having unspecified (and broad) amino acid sequences for CDRs 1 and 2.

    The Court also rejected BAC's arguments that the specification disclosed "how to identify VHH antigen-binding proteins" by functional and structural characteristics.  This is insufficient to satisfy the written description requirement in view of the specification only disclosing a single VHH antigen-binding protein species, according to the panel.

    The opinion also notes that "BAC does not challenge the Board's findings that the '082 application discloses only one VHH antigen-binding protein that meets each of the limitations claim of 77, and that the '082 application does not disclose a common structural feature for the claimed VHH antigen-binding proteins" as grounds for affirming the Board's rejection of BAC's appeal of the examiner's final rejection.

    The decision in many ways is a "garden variety" written description rejection based on thirty years of written description jurisprudence that began with Judge Lourie's decision in Regents of the University of California v. Eli Lilly & Co. (indeed, the decision recites the standard from that case that satisfaction of the requirement can be achieved by disclosing a "representative number of species" in a claimed genus or a structure/function relationship for species falling within the scope of the claimed genus).  If nothing else, decisions such as these illustrate the continuing consistency of the Court's written description jurisprudence.

    * The opinion notes that at least one claim would be allowable, if amended so as not to depend on a rejected base claim; that claim recited a specific VHH species.

    In re BAC IP B.V. (Fed. Cir. 2025)
    Nonprecedential disposition
    Panel: Circuit Judges Lourie, Prost, and Stoll
    Opinion by Circuit Judge Lourie

  • By Kevin E. Noonan

    Federal Circuit SealUnder Dickinson v. Zurko courts (specifically, the Federal Circuit) should defer to factual determinations by administrative agencies like the U.S. Patent and Trademark Office unless they are not supported by substantial evidence, pursuant to the provisions of the Administrative Procedure Act (codified at 5 U.S.C. § 706).  Such deference is not plenary, and when the Office (or more specifically, the Patent Trial and Appeal Board) renders a decision that does not sufficiently show its reasoning regarding relevant facts to support its findings the court should, at a minimum, vacate the decision and remand with the benefit of the Court's thinking on the matter.  Such was the case in the Federal Circuit's recent decision in American Science and Engineering, Inc. v. Stewart (nonprecedential).

    The case arose in an inter partes review proceeding brought by Petitioner Viken Detection Corp., challenging the claims of American Science's U.S. Patent No. 7,400,701 on anticipation grounds over U.S. Patent No. 7,672,422 and for obviousness over the combination of the '422 patent and U.S. Patent Nos. 6,459,764 or 6,459,764.  The '701 patent was directed to an inspection system wherein an object was subjected to "multiple sources of penetrating radiation"; Claim 1 was set forth in the opinion as being representative:

    1.  An inspection system for inspecting an object characterized by motion in a direction with respect to the inspection system, the system comprising:
        a.  a first pencil-beam source for providing a first beam of penetrating radiation of specified cross-section directed in a first beam direction substantially transverse to the direction of motion of the object;
        b.  a second pencil-beam source for providing a second beam of penetrating radiation of specified cross-section substantially coplanar with, and substantially perpendicular to, the first beam of penetrating radiation, directed in a second beam direction, and temporally interspersed with the first beam of penetrating radiation;
        c.  a plurality of scatter detectors each scatter detector of which is disposed so as to detect radiation scattered from both the first beam and the second beam by any scattering material within the inspected object and for generating a scattered radiation signal; and
        d.  a controller for creating an image of the scattering material based solely on the scattered radiation signal.

    (wherein the italicized language denotes claim elements relevant to the issues between the parties).

    The PTAB found claims 1-4 and 10-13 to be anticipated by the '422 patent and claims 5-9 to be obvious under combinations of the asserted prior art.  Although Viken withdrew from this appeal before briefing had concluded, the Acting Director intervened as appellee and filed a brief responsive to American Science's appeal.

    The Federal Circuit vacated and remanded, in an opinion by Chief Judge Moore joined by Judges Linn and Cunningham.  The Court agreed with American Science's argument that the Board erred because it did not find that the "scatter detectors [disclosed in the '422 patent] can detect scattered radiation from two perpendicular pencil beam sources" as required by the '701 challenged patent claims.  The panel found that the '701 patent disclosed "substantially perpendicular" pencil beam sources that were surrounded by "a plurality of scatter detectors disposed to detect radiation scattered from the perpendicular beams."  The '422 patent, on the other hand, teaches "additional detectors" but "is silent as to whether the additional detectors detect radiation from multiple pencil beam sources"; this configuration is illustrated by this drawing reproduced in the opinion:

    Fig. 1While the panel recognized that the Board found the additional detectors were "capable of detecting backscatter radiation from both pencil beams because [the '422 patent] discloses cycling pencil beam sources such that only one source is turned on at a time," in the panel's opinion the Board "never expressly found [the '422 patent's] additional detectors detect radiation from both pencil beams when the beams are in a 'substantially perpendicular' arrangement" as claimed, and thus did not satisfy the requirements for anticipation that "every limitation in the claim was identically shown in the single reference" under Gechter v. Davidson, 116 F.3d 1454, 1460 (Fed. Cir. 1997).  The Acting Director responded to this assertion of Board error by arguing that "the '701 patent repeatedly acknowledges that radiation scatters from an object in all directions so the additional detectors detect at least some radiation from all of [the '422 patent's] pencil beam sources."  But the Court considered that the Board "made no findings about the '701 patent's disclosure of how radiation scatters that allow [the panel] to discern the path of [the Board's] reasoning," which contravenes the rubric enunciated in In re Nuvasive, Inc., 842 F.3d 1376, 1383 (Fed. Cir. 2016), that "[t]he PTAB's own explanation must suffice for us to see that the agency has done its job and must be capable of being 'reasonably . . . discerned' from a relatively concise PTAB discussion."  The Court also rejected the Acting Director's argument that the Petition and Viken's expert witness's testimony supported its determination that the '422 patent's "additional detectors would detect radiation scattered from all sources."  The opinion characterizes this argument as comprising "a citation within citation" that does not allow the Court to determine whether the Board's bases for its opinion followed the "proper path" because it amounted to "conclusory assertions and lack of explanation or reasoning."  The panel thus vacated the Board's decision because "the Board has failed to provide us with reasoning that is reviewable on appeal for its finding that [the '422 patent's] additional detectors detect scattered radiation from substantially perpendicular pencil beams" as required to support its finding that claims 1-4 and 10-13 of the '701 patent were anticipated by the '422 patent disclosure.  Without analysis the Court also vacated and remanded the Board's determination that claims 5-9 of the '701 patent were obvious, based on the same failure by the Board to explain its reasoning regarding the '422 patent disclosure.

    American Science and Engineering, Inc. v. Stewart (Fed. Cir. 2025)
    Nonprecedential disposition
    Panel: Chief Judge Moore and Circuit Judges Linn and Cunningham
    Opinion by Chief Judge Moore

  • By Kevin E. Noonan

    Judge Newman_1Inexorable, inevitable, and regrettable are three words that come to mind with publication from the Report from Special Committee of the Federal Circuit (composed of Chief Judge Moore and Judges Prost and Taranto) containing, inter alia, their recommendation that suspension of Judge Pauline Newman be extended for yet another year.

    The basis for the sanction remains the same:  that Judge Newman's continued refusal to submit to the Special Committee's appointed physicians is judicial misconduct.  The Report is 95 pages in length and sets forth those spurned physicians' justifications for arguing that their examination (and not Judge Newman's own qualified physicians') are required.  Those arguments include that "[t]he Committee finds that this extensive record leaves no room for doubt:  Judge Newman, now 98 years old, needs a full neuropsychological battery of tests in order for the Committee to determine whether she is capable of performing the functions of an active federal judge" (the reference to the Judge's age not being close to coincidental).  The Report strongly suggests that the report by Judge Newman's physician (Dr. Rothstein) on her neurological health is less robust that presented in her attorney's arguments.  The Report also cast doubts on Dr. Carney's opinion regarding Judge Newman's neurological fitness to serve.  And the Report asserts that "[a]ll three" of the Committee's experts "explained, in detail, that, contrary to the assertions made by Judge Newman's expert, Dr. Filler, it is not an accepted diagnostic approach in the field to use a CT perfusion scan to determine whether or not an individual suffers from a cognitive impairment" (supplemented by additional allegations of professional incredibility on Dr. Filler's part, including mistakes regarding Judge Newman's fainting incidents).  The Report also includes evidence from the Judge's medical records of "memory impairment" issues as early as 2022 and that the Judge made "significant errors" in recounting her own medical history to her doctors in 2023 and 2024.

    Of the evidence and testimony from "non-professional" witnesses, the Report mentions the "more than a dozen affidavits from court employees from nearly every court department" as raising "serious concerns" regarding the Judge's neurological health.  This evidence, while helping to paint a picture of the Judge being in cognitive decline is less relevant first for being lay testimony on a medical issue for which the witnesses are not competent to opine and second because the issue is not whether prudence suggests the Judge's neurophysiological state be assessed, but rather the Committee's insistence that Judge Newman comply with their demands that their physicians do the assessing.

    The summary section of the Report ends by placing the blame for the current circumstances on the Judge, stating that "[y]ears of litigating this dispute could have been avoided if Judge Newman had acknowledged in 2023 that the neurologist she selected—Dr. Ted Rothstein—recommended that she have the more detailed neuropsychological testing and if she had followed his advice and acquiesced in having that testing."

    The Report's conclusions contain three recommendations (characterized elsewhere in the Report as "recommended sanction for continuing misconduct"):

    (i) that there is a reasonable basis to order full neuropsychological testing by a provider selected by the Committee;

    (ii) that Judge Newman's continued refusal to cooperate with the Committee's investigation by undergoing that testing constitutes continuing misconduct; and

    (iii) that the Judicial Council should renew the sanction of suspending Judge Newman from hearing cases for a period of one year.

    As Judge Newman has maintained, following these recommendations could be considered to be a de facto impeachment of an Article III judge regardless of how it is presented.

    The remainder of the Report provides an extensive recapitulation of the procedural and evidentiary background of this matter, specifically directed at evidence that casts doubt on the conclusions drawn by Judge Newman's experts, the validity of the testing they did perform, and whether they themselves evinced as much faith in those conclusions than has been represented they did in various court filings and briefs both before the Committee and in the lawsuit brought by Judge Newman in the D.C. District Court and Circuit Court (see "Judge Newman Files Appeal with D.C. Circuit").  Regarding the Committee's own experts, the Report provides their professional imprimatur on the insistence that Judge Newman submit to examination by them as "independent experts" based at least in part on the deficiencies alleged against the physicians picked by the Judge herself.  Finally, the Report attempts to rebut the anecdotal evidence by those who have heard Judge Newman speak during the term of her suspensions by stating that "[e]vidence suggesting that Judge Newman can speak coherently and fluidly does not undermine the need for testing."

    Unless the D.C. Court of Appeals finds in Judge Newman's favor it can only be presumed that she has spent her last day as an active Judge on the Federal Circuit bench.